Trials / Unknown
UnknownNCT05950516
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection (QLG2065) vs. Ozempic® as add-on to Metformin in Type 2 Diabetics.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 478 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the similarity of the efficacy and safety of semaglutide injection (QLG2065) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks |
| DRUG | Semaglutide Pen Injector [Ozempic] | Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks |
Timeline
- Start date
- 2023-07-10
- Primary completion
- 2024-11-24
- Completion
- 2025-01-22
- First posted
- 2023-07-18
- Last updated
- 2023-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05950516. Inclusion in this directory is not an endorsement.